Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia
A Prospective, Natural History Study to Assess the Occurrence of HPA-1a Alloimmunization in Women Identified at Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Sponsor: Rallybio
Listed as NCT05345561, this observational or N/A phase trial focuses on Fetal and Neonatal Alloimmune Thrombocytopenia and remains completed. Sponsored by Rallybio, it has been updated 13 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Mar 2026 — Present [monthly]
Completed
-
Dec 2025 — Mar 2026 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Jul 2025 — Dec 2025 [monthly]
Active Not Recruiting
-
Mar 2025 — Jul 2025 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Feb 2025 — Mar 2025 [monthly]
Recruiting
▶ Show 8 earlier versions
-
Sep 2024 — Feb 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
May 2024 — Jul 2024 [monthly]
Recruiting
-
Jan 2024 — May 2024 [monthly]
Recruiting
-
Aug 2023 — Jan 2024 [monthly]
Recruiting
-
Apr 2023 — Aug 2023 [monthly]
Recruiting
-
Sep 2022 — Apr 2023 [monthly]
Recruiting
-
May 2022 — Sep 2022 [monthly]
Recruiting
First recorded
Mar 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Rallybio
For direct contact, visit the study record on ClinicalTrials.gov .